Lisa Manig1, Stefan Janssen1, Steven E Schild2, Dirk Rades3. 1. Department of Radiation Oncology, University of Lübeck, Lübeck, Germany. 2. Department of Radiation Oncology, Mayo Clinic, Scottsdale, AZ, U.S.A. 3. Department of Radiation Oncology, University of Lübeck, Lübeck, Germany rades.dirk@gmx.net.
Abstract
AIM: To create a tool to estimate overall survival (OS) of patients with non-metastatic bladder cancer. PATIENTS AND METHODS: Eight parameters were retrospectively evaluated for OS in 42 patients undergoing radiotherapy and upfront transurethral resection for bladder cancer. The prognostic tool included those parameters that were significant on both univariate and multivariate analyses. The tool was based on the 3-year OS rate divided by 10. Patient scores were calculated by adding the points for each significant parameter. RESULTS: On univariate analysis, 3-year OS was associated with gender (p=0.017), pack years (p=0.009) and Karnofsky performance score (KPS) (p<0.001). On Cox regression, pack years (p=0.007) and KPS (p<0.001) remained significant and were incorporated into the tool. Three prognostic groups were designated with 6, 10-11 and 15 points with 3-year OS-rates of 0%, 34% and 83%, respectively (p<0.001). CONCLUSION: A tool was developed to estimate the OS of patients with bladder cancer to improve individualization of treatment. Copyright
AIM: To create a tool to estimate overall survival (OS) of patients with non-metastatic bladder cancer. PATIENTS AND METHODS: Eight parameters were retrospectively evaluated for OS in 42 patients undergoing radiotherapy and upfront transurethral resection for bladder cancer. The prognostic tool included those parameters that were significant on both univariate and multivariate analyses. The tool was based on the 3-year OS rate divided by 10. Patient scores were calculated by adding the points for each significant parameter. RESULTS: On univariate analysis, 3-year OS was associated with gender (p=0.017), pack years (p=0.009) and Karnofsky performance score (KPS) (p<0.001). On Cox regression, pack years (p=0.007) and KPS (p<0.001) remained significant and were incorporated into the tool. Three prognostic groups were designated with 6, 10-11 and 15 points with 3-year OS-rates of 0%, 34% and 83%, respectively (p<0.001). CONCLUSION: A tool was developed to estimate the OS of patients with bladder cancer to improve individualization of treatment. Copyright
Authors: R Granata; R Miceli; E Orlandi; F Perrone; B Cortelazzi; M Franceschini; L D Locati; P Bossi; C Bergamini; A Mirabile; L Mariani; P Olmi; G Scaramellini; P Potepan; P Quattrone; K K Ang; L Licitra Journal: Ann Oncol Date: 2011-11-24 Impact factor: 32.976
Authors: Deepak Kilari; Kenneth A Iczkowski; Chintan Pandya; Adam J Robin; Edward M Messing; Elizabeth Guancial; Eric S Kim Journal: Anticancer Res Date: 2016-02 Impact factor: 2.480
Authors: Bryan M Hancock; Kathleen L McGuire; Shingo Tsuji; Katherine Reil; Veronica Hernandez; Matthew J Giacalone; W T Godbey Journal: Anticancer Res Date: 2016-12 Impact factor: 2.480
Authors: Claus Rödel; Gerhard G Grabenbauer; Reinhard Kühn; Thomas Papadopoulos; Jürgen Dunst; Martin Meyer; Karl M Schrott; Rolf Sauer Journal: J Clin Oncol Date: 2002-07-15 Impact factor: 44.544
Authors: Dirk Rades; Liesa Dziggel; Lisa Manig; Stefan Janssen; Mai Trong Khoa; Vuong Ngoc Duong; Vu Huu Khiem; Steven E Schild Journal: In Vivo Date: 2018 May-Jun Impact factor: 2.155